Oskar Hansson
YOU?
Author Swipe
View article: Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid
Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid Open
Brain amyloid-β (Aβ) pathology is a core feature of Alzheimer disease (AD) and can be quantified using positron emission tomography (PET). Cerebrospinal fluid (CSF) and plasma biomarkers detect abnormal Aβ, but it is unclear to what degree…
View article: Locus coeruleus‐entorhinal cortex tract integrity is linked to plasma tau and glial fibrillary acidic protein
Locus coeruleus‐entorhinal cortex tract integrity is linked to plasma tau and glial fibrillary acidic protein Open
INTRODUCTION Pretangle tau inclusions from the locus coeruleus (LC) are hypothesized to propagate to the entorhinal cortex (EC) via neuron‐to‐neuron transmission along its projections. The lower integrity of the LC‐EC pathway accompanying …
View article: Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?
Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility? Open
Background Phosphorylated tau 217 (p-tau217) has emerged as a leading blood-based biomarker for Alzheimer disease (AD). While typically measured in plasma, serum is a widely used matrix in clinical laboratories, yet few p-tau217 assays hav…
View article: Taurine Intake, Plasma Taurine Concentration, and Dementia Risk: Findings From the Malmö Diet and Cancer Study
Taurine Intake, Plasma Taurine Concentration, and Dementia Risk: Findings From the Malmö Diet and Cancer Study Open
Preclinical studies suggest that taurine may exert neuroprotective effects. However, its relevance to dementia risk in human populations remains unclear. We investigated the associations between mid‐life dietary taurine intake, circulating…
View article: Assessment of myocardial sympathetic innervation with [123I]mIBG myocardial scintigraphy: A comparative study between an Anger and a ring-configured cadmium-zinc-telluride gamma camera
Assessment of myocardial sympathetic innervation with [123I]mIBG myocardial scintigraphy: A comparative study between an Anger and a ring-configured cadmium-zinc-telluride gamma camera Open
Determining HMR from reprojected [123I]mIBG myocardial scintigraphy planar images acquired with a ring-configured CZT gamma camera is feasible and shows good agreement with HMR determined from planar images by a conventional Anger gamma ca…
View article: Estimating the time course of biomarker changes in Alzheimer’s disease
Estimating the time course of biomarker changes in Alzheimer’s disease Open
Recent advancements in biomarkers have transformed Alzheimer’s disease (AD) diagnosis from being purely symptom-based to include biological criteria. With new treatments targeting AD’s core biology, understanding the timeline of biological…
View article: Plasma p-tau <sub>217</sub> correlates strongly with cerebrospinal fluid Aβ <sub>42</sub> and increases over a ten-year period in amyloid-positive, non-demented very old men
Plasma p-tau <sub>217</sub> correlates strongly with cerebrospinal fluid Aβ <sub>42</sub> and increases over a ten-year period in amyloid-positive, non-demented very old men Open
Background Plasma phosphorylated tau 217 (p-tau 217 ) is a robust biomarker of Alzheimer's disease (AD) pathology. However, its full potential as a dynamic marker has still not been verified in very old persons, i.e., those with the highes…
View article: Biological classification of memory clinic patients
Biological classification of memory clinic patients Open
Neurodegenerative diseases have traditionally been defined in vivo based on clinical symptoms. However, the development of biomarkers has enabled a shift toward in vivo biological definitions. There is now a need to characterize memory cli…
View article: P-TAU205 IS A BIOMARKER LINKED TO TAU-PET ABNORMALITY: A CROSS-SECTIONAL AND LONGITUDINAL STUDY
P-TAU205 IS A BIOMARKER LINKED TO TAU-PET ABNORMALITY: A CROSS-SECTIONAL AND LONGITUDINAL STUDY Open
Current fluid biomarkers for Alzheimer’s disease (AD) track amyloid-β (Aβ) pathology more strongly than tau, even though clinical and cognitive decline relate more closely to tau. We evaluated cerebrospinal fluid (CSF) phosphorylated tau a…
View article: Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease Open
Importance Accumulation of amyloid plaque drives pathogenesis of Alzheimer disease (AD). Reduction of amyloid via amyloid-targeting therapies may result in clinical benefit. Objective To assess the correlation of posttreatment amyloid leve…
View article: Reference proteins to improve Core 1 and Core 2 Alzheimer’s disease CSF and plasma biomarkers
Reference proteins to improve Core 1 and Core 2 Alzheimer’s disease CSF and plasma biomarkers Open
Concentration-based fluid biomarkers represent an informative and cost-effective way to detect and monitor Alzheimer’s disease (AD) pathology. However, non-AD-related inter-individual variation in biofluids can also affect biomarker concen…
View article: Patient-specific functional brain architecture explains cortical patterns of tau PET in Alzheimer's disease
Patient-specific functional brain architecture explains cortical patterns of tau PET in Alzheimer's disease Open
The spatial distribution of tau pathology, the core driver of neurodegeneration in Alzheimer's disease (AD), varies markedly across individuals. While tau is thought to spread along brain networks, the role of inter-individual variability …
View article: How can Alzheimer's disease blood‐based biomarkers reach clinical practice?
How can Alzheimer's disease blood‐based biomarkers reach clinical practice? Open
INTRODUCTION Alzheimer's disease (AD) diagnosis has been based largely on clinical symptoms, despite their limited sensitivity and specificity. Biomarker use was proposed to support a more accurate and timely diagnosis. However, neuroimagi…
View article: Complementary utility of plasma biomarkers and Aβ‐PET for diagnosis, risk‐stratification, and treatment monitoring in Alzheimer's disease
Complementary utility of plasma biomarkers and Aβ‐PET for diagnosis, risk‐stratification, and treatment monitoring in Alzheimer's disease Open
With the rapid development of blood biomarkers (BBMs) related to amyloid‐β (Aβ) pathology in Alzheimer's disease (AD), the question arises whether these can replace the accepted reference standard, positron emission tomography (PET), for a…
View article: Evidence‐based standardized sample handling protocol for accurate blood‐based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium
Evidence‐based standardized sample handling protocol for accurate blood‐based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium Open
INTRODUCTION Blood‐based biomarkers (BBMs) have revolutionized Alzheimer's disease diagnosis and monitoring. Their pre‐analytical stability requires scrutiny. This study assessed pre‐analytical effects to inform a standardized sample handl…
View article: Reversible tau hyperphosphorylation in hibernation: a blood biomarker and brain tissue study
Reversible tau hyperphosphorylation in hibernation: a blood biomarker and brain tissue study Open
Tau hyperphosphorylation, a key neuropathological feature of tauopathies such as Alzheimer’s disease (AD), also occurs physiologically during mammalian hibernation and is fully reversed upon arousal, offering a unique translational model t…
View article: Alzheimer's disease diagnostic progression is associated with cerebrovascular disease and neuroinflammation in adults with Down syndrome
Alzheimer's disease diagnostic progression is associated with cerebrovascular disease and neuroinflammation in adults with Down syndrome Open
INTRODUCTION Despite having few vascular risk factors, people with Down syndrome (DS) have MRI evidence of cerebrovascular disease (CVD) and neuroinflammation that worsens with Alzheimer's disease (AD) severity. We investigated whether mar…
View article: Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease
Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease Open
Importance Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective To assess t…
View article: Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers
Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers Open
After the clinical implementation of amyloid-β-targeting therapies for people with cognitive impairment due to Alzheimer’s disease (AD), there is an urgent need to efficiently identify this patient population in primary care. Therefore, we…
View article: Visual Classification of Tau-PET Detects 4 Subtypes With Different Long-Term Outcomes
Visual Classification of Tau-PET Detects 4 Subtypes With Different Long-Term Outcomes Open
Visual classification reliably identified 4 tau patterns that differ in global tau load, clinical features, and long-term outcomes, suggesting its clinical usefulness for the detection of higher-risk AD variants. A clinically implementable…
View article: Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer’s Disease
Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer’s Disease Open
The distribution of tau pathology in Alzheimer’s disease (AD) shows remarkable inter-individual heterogeneity, including hemispheric asymmetry. However, the factors driving this asymmetry remain poorly understood. Here we explore whether t…
View article: Evaluation of a Sensitive Visual Read Algorithm for Assessing 3R/4R Tau PET Images
Evaluation of a Sensitive Visual Read Algorithm for Assessing 3R/4R Tau PET Images Open
Developing and validating sensitive visual read algorithms for assessing Alzheimer disease-related tau in tau PET imaging is imperative, considering the implementation of the methodology in clinical practice and trials. Our aim was to comp…
View article: Alzheimer's disease outlook: controversies and future directions
Alzheimer's disease outlook: controversies and future directions Open
For the first time, reductions in cerebral β-amyloid pathology load and rate of cognitive and functional decline have been achieved in Alzheimer's disease, through pharmacological intervention in randomised controlled trials. However, the …
View article: New landscape of the diagnosis of Alzheimer's disease
New landscape of the diagnosis of Alzheimer's disease Open
Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and…
View article: Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals
Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals Open
INTRODUCTION Plasma biomarkers’ utility for predicting incident mild cognitive impairment (MCI) remains unclear. We evaluated associations of plasma Alzheimer's disease (AD) biomarkers and amyloid positron emission tomography (PET) with tr…
View article: CSF markers of neuroinflammation, synaptic dysfunction and [18F]DOPA-PET in Parkinson's disease
CSF markers of neuroinflammation, synaptic dysfunction and [18F]DOPA-PET in Parkinson's disease Open
In PD patients, a decrease in [18F]DOPA PET retention correlated with disease duration as well as CSF neurodegenerative and synaptic biomarkers but not with inflammatory biomarkers or [18F]RO948 PET midbrain off-target retention.
View article: Olfactory dysfunction and amyloid-positivity in Parkinson’s disease—longitudinal analysis of cognitive decline and cerebrospinal fluid markers
Olfactory dysfunction and amyloid-positivity in Parkinson’s disease—longitudinal analysis of cognitive decline and cerebrospinal fluid markers Open
Background Olfactory dysfunction is a common non-motor symptom in Parkinson’s disease (PD). The objective was to evaluate the association between olfaction in PD with cross-sectional and longitudinal assessments of clinical variables and n…
View article: Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease
Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease Open
The link between regional tau load and clinical manifestation of Alzheimer’s disease (AD) highlights the importance of characterizing spatial tau distribution across disease variants. In typical (memory-predominant) AD, the spatial progres…